Semintra

RSS

telmisartan

Authorised
This medicine is authorised for use in the European Union.

Overview

An overview of Semintra and why it is authorised in the EU

Semintra is a veterinary medicine used in cats to reduce proteinuria (protein in the urine) and to treat high blood pressure. Proteinuria can occur with chronic (long-term) kidney disease in cats, a common disease in elderly cats characterised by a progressive deterioration of kidney function over time. High blood pressure is also a long term problem of ageing cats which can occur with chronic kidney disease, hyperthyroidism (overactive thyroid gland) and other conditions.

This EPAR was last updated on 25/06/2018

Authorisation details

Product details
Name
Semintra
Agency product number
EMEA/V/C/002436
Active substance
telmisartan
International non-proprietary name (INN) or common name
telmisartan
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QC09CA07
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
12/02/2013
Contact address
Binger Strasse 73
55216 Ingelheim am Rhein
Germany

Product information

08/05/2018 Semintra - EMEA/V/C/002436 - X/0008

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Agents acting on the renin angiotensin system
  • angiotensin II antagonists
  • plain.

Therapeutic indication

Reduction of proteinuria associated with chronic kidney disease (CKD).

Assessment history

How useful was this page?

Add your rating